Literature DB >> 32065507

Adherence to antihypertensive drug treatment in Argentina: A multicenter study.

Walter Espeche1,2, Martin R Salazar1,2, Rodrigo Sabio3, Alejandro Diaz4, Carlos Leiva Sisnieguez1,2, Daniel Olano1, Eduardo Balbin1, Nicolas Renna5, Pedro Grosse6, Roberto A Flores7, Ana C Lagos8, Pablo Ferrer9, Silvia Poppe10, Facundo Risso Patron11, Victor D Sotnieczuk Stasiuk12, Elina Valentini13, Jose R Cardozo14, Jose R Romano15, Roberto Parodi16, Horacio Carbajal2.   

Abstract

Adherence to antihypertensive medication is an important challenge that doctors often face in the treatment of hypertension. Good adherence is crucial to prevent cardiovascular complications. In consequence, the present study aimed at determining the prevalence of adherence to antihypertensive treatment and identifying associated clinical variables. A multicenter cross-sectional study was conducted in 12 cities of Argentina. A systematic sampling was performed in order to select patients with hypertension and under pharmacological treatment for at least 6 months. Physicians took three BP measurements, and the level of adherence was assessed using the self-administered Morisky questionnaire (MMAS-8). Participants were classified into three levels of adherence: high adherence-MMAS score of 8; medium adherence-MMAS scores of 6 to <8; and low adherence-MMAS scores of <6. A total of 1111 individuals (62 ± 12 years old, women 49.4%) were included in the present analysis; 159 (14.3%), 329 (29.6%) and 623 (56.1%) patients had low, medium, and high adherence, respectively. The prevalence of controlled hypertension increased only in high adherent patients: 42.8%, 42.2%, and 64.5% for low, medium, and high adherence groups, respectively. Similarly, systolic BP was lower only in the high adherence group. High educational level (OR 3.47, 95% CI 2.68-4.49) and diuretic treatment (OR 0.64, 95% CI 0.47-0.88) were independent predictors of high adherence. In conclusion, more than a half of treated hypertensive patients had a high level of adherence. These patients had lower BP values and higher control levels. A high educational level predicts high adherence.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  adherence; antihypertensive drugs; cross-sectional study

Mesh:

Substances:

Year:  2020        PMID: 32065507      PMCID: PMC8029743          DOI: 10.1111/jch.13830

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  20 in total

1.  2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  J Hypertens       Date:  2018-10       Impact factor: 4.844

Review 2.  Factors associated with antihypertensive medication non-adherence: a systematic review.

Authors:  D M van der Laan; P J M Elders; C C L M Boons; J J Beckeringh; G Nijpels; J G Hugtenburg
Journal:  J Hum Hypertens       Date:  2017-06-29       Impact factor: 3.012

3.  Meta-analysis: impact of drug class on adherence to antihypertensives.

Authors:  Ian M Kronish; Mark Woodward; Ziad Sergie; Gbenga Ogedegbe; Louise Falzon; Devin M Mann
Journal:  Circulation       Date:  2011-04-04       Impact factor: 29.690

4.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.

Authors:  Sayed H Naderi; Jonathan P Bestwick; David S Wald
Journal:  Am J Med       Date:  2012-06-27       Impact factor: 4.965

5.  The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults.

Authors:  Alfredo Dias de Oliveira-Filho; Donald E Morisky; Sabrina Joany Felizardo Neves; Francisco A Costa; Divaldo Pereira de Lyra
Journal:  Res Social Adm Pharm       Date:  2013-10-26

6.  Association between depressive and anxiety disorders and adherence to antihypertensive medication in community-living elderly adults.

Authors:  Lia Gentil; Helen Maria Vasiliadis; Michel Préville; Cindy Bossé; Djamal Berbiche
Journal:  J Am Geriatr Soc       Date:  2012-10-30       Impact factor: 5.562

7.  Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults.

Authors:  Virginie Korb-Savoldelli; Florence Gillaizeau; Jacques Pouchot; Emilie Lenain; Nicolas Postel-Vinay; Pierre-François Plouin; Pierre Durieux; Brigitte Sabatier
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04-26       Impact factor: 3.738

8.  Blood pressure control and cardiovascular risk profile in hypertensive patients under specialist care in Argentina: Results from the CHARTER study.

Authors:  Marcos Marín; Jessica Barochiner; Pablo Rodríguez; Nicolás Renna; Carlos Castellaro; Walter Espeche; Alejandro De Cerchio; Mildren Del Sueldo; Sergio Vissani; Judith Zilberman
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-03       Impact factor: 3.738

Review 9.  Nonadherence to antihypertensive drugs: A systematic review and meta-analysis.

Authors:  Tadesse Melaku Abegaz; Abdulla Shehab; Eyob Alemayehu Gebreyohannes; Akshaya Srikanth Bhagavathula; Asim Ahmed Elnour
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

10.  Self-Reported Medication Adherence Measured With Morisky Medication Adherence Scales and Its Determinants in Hypertensive Patients Aged ≥60 Years: A Systematic Review and Meta-Analysis.

Authors:  Bartosz Uchmanowicz; Ewa A Jankowska; Izabella Uchmanowicz; Donald E Morisky
Journal:  Front Pharmacol       Date:  2019-03-01       Impact factor: 5.810

View more
  5 in total

Review 1.  Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries.

Authors:  Eleanor Bruyn; Long Nguyen; Aletta E Schutte; Adrianna Murphy; Pablo Perel; Ruth Webster
Journal:  Glob Heart       Date:  2022-01-25

Review 2.  Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients.

Authors:  Eric K P Lee; Paul Poon; Benjamin H K Yip; Yacong Bo; Meng-Ting Zhu; Chun-Pong Yu; Alfonse C H Ngai; Martin C S Wong; Samuel Y S Wong
Journal:  J Am Heart Assoc       Date:  2022-09-03       Impact factor: 6.106

3.  Medication regimen complexity and its association with adherence and blood pressure control among hypertensive patients at selected hospitals of South Gondar Zone: A hospital based cross sectional study.

Authors:  Taklo Simeneh Yazie; Workneh Ebabu Mengistu; Zemen Asmare; Abebe Muche Belete; Assefa Agegnehu Teshome; Yohannes Shumet Yimer
Journal:  PLoS One       Date:  2022-08-18       Impact factor: 3.752

4.  Adherence to antihypertensive drug treatment in Argentina: A multicenter study.

Authors:  Walter Espeche; Martin R Salazar; Rodrigo Sabio; Alejandro Diaz; Carlos Leiva Sisnieguez; Daniel Olano; Eduardo Balbin; Nicolas Renna; Pedro Grosse; Roberto A Flores; Ana C Lagos; Pablo Ferrer; Silvia Poppe; Facundo Risso Patron; Victor D Sotnieczuk Stasiuk; Elina Valentini; Jose R Cardozo; Jose R Romano; Roberto Parodi; Horacio Carbajal
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-17       Impact factor: 3.738

5.  Early adherence to antihypertensive drugs and long-term cardiovascular mortality in the "real world".

Authors:  Martin R Salazar
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-07-13       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.